Ljiljana Fodor Duric

Dr. Ljiljana Fodor Duric

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LDLjiljana Fodor Duric
Ljiljana Fodor Duric
VBVelimir Belcic
Velimir Belcic
AKAnja Oberiter Korbar
Anja Oberiter Korbar
SĆSanja Ćurković
Sanja Ćurković
Bozidar VujicicBozidar Vujicic
Bozidar Vujicic
ECEdina Catic Cuti
Edina Catic Cuti
Background: Metabolic-associated fatty liver disease (MAFLD) is a spectrum of liver diseases linked to insulin resistance (IR), type 2 diabetes, and metabolic disorders. IR accelerates fat accumulation in the liver, worsening MAFLD. Regular physical activity and weight loss can improve liver function, reduce fat, and lower cardiovascular risk. This study examines the role of sex hormone-binding globulin (SHBG) in MAFLD, focusing on its potential as a biomarker and its relationship with insulin resistance. Methods: The study included 98 male patients (ages 30–55) with MAFLD, identified through systematic examinations, and 74 healthy male controls. All participants underwent abdominal ultrasound and blood tests after fasting, assessing markers such as glucose, liver enzymes (AST, ALT, γGT), lipids (cholesterol, triglycerides), insulin, SHBG, estradiol, and testosterone. SHBG levels were analyzed in relation to body mass index (BMI) and age. Results: A significant association was found between low SHBG levels and the presence of fatty liver. Individuals with MAFLD had lower SHBG levels compared to controls. BMI and age were key factors influencing SHBG, with higher BMI linked to lower SHBG in younger men, while SHBG remained stable in older individuals regardless of BMI. Conclusion: SHBG may serve as a valuable biomarker for early detection and risk assessment of MAFLD. The complex relationship between SHBG, BMI, and age highlights the importance of considering both hormonal and metabolic factors when assessing fatty liver risk. Our findings support the need for comprehensive metabolic evaluations in clinical practice.

27 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LDLjiljana Fodor Duric
Ljiljana Fodor Duric
Nikolina Basic-JukicNikolina Basic-Jukic
Nikolina Basic-Jukic
Bozidar VujicicBozidar Vujicic
Bozidar Vujicic
Regenerative medicine shows significant potential in treating kidney diseases through the application of various types of stem and progenitor cells, including mesenchymal stem cells (MSCs), renal stem/progenitor cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). Stem cells possess the unique ability to repair injured organs and improve impaired functions, making them a key element in the research of therapies for kidney tissue repair and organ regeneration. In kidney transplantation, reperfusion injury can cause tissue destruction, leading to an initially low glomerular filtration rate and long-term impact on function by creating irreversible interstitial fibrosis. MSCs have proven useful in repairing early tissue injury in animal models of kidney, lung, heart, and intestine transplantation. The use of stem cell therapies in solid organ transplantation raises the question of whether autologous or allogeneic cells should be preferred. Adipose-derived stem cells (ASCs), characterized by the lack of HLA Class II molecules and low expression of HLA Class I and co-stimulatory signals, are considered immune-privileged. However, the actual risk of graft rejection associated with allogeneic ASCs remains unclear. It has been demonstrated that donor-derived ASCs can promote the development of Treg cells in vitro, and some degree of tolerance induction has been observed in vivo. Nevertheless, a study comparing the efficacy of autologous and allogeneic ASCs in a rat model with a total MHC mismatch for kidney transplantation showed that donor-derived administration of ASCs did not improve the grafts’ survival and was associated with increased mortality through an immunologically mediated mechanism. Given the lack of data, autologous ASCs appear to be a safer option in this research context. The aim of this review was to examine the differences between autologous and allogeneic ASCs in the context of their application in kidney transplantation therapies, considering potential immune reactions and therapeutic efficacy. Some have argued that ASCs harvested from end-stage renal disease (ESRD) patients may have lower regenerative potential due to the toxic effects of uremia, potentially limiting their use in transplantation settings. However, evidence suggests that the beneficial properties of ASCs are not affected by uremia or dialysis. Indeed, some investigators have demonstrated that ASCs harvested from chronic kidney disease (CKD) patients exhibit normal characteristics and function, maintaining consistent proliferative capacity and genetic stability over time, even after prolonged exposure to uremic serum Furthermore, no differences were observed in the response of ASCs to immune activation or their inhibitory effect on the proliferation of alloantigen-activated peripheral blood mononuclear cells between patients with normal or impaired renal function. This review presents the current achievements in stem cell research aimed at treating kidney diseases, highlighting significant progress and ongoing efforts in the development of stem cell-based therapies. Despite the encouraging results, further research is needed to overcome the current limitations and fully realize the potential of these innovative treatments. Advances in this field are crucial for developing effective therapies that can address the complex challenges associated with kidney damage and failure.

6 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LDLjiljana Fodor Duric
Ljiljana Fodor Duric
ZRZrinka Colak Romic
Zrinka Colak Romic
DPDino Pavičić
Dino Pavičić
JĆJosip Josip Ćurić
Josip Josip Ćurić
VBVelimir Belcic
Velimir Belcic
AKAnja Oberiter Korbar
Anja Oberiter Korbar
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with insulin resistance and metabolic disturbances. Sex hormone-binding globulin (SHBG) is closely linked to metabolic regulation and has been shown to differ between individuals with and without MASLD. Objective: This study aimed to investigate the associations between SHBG and MASLD and their relationships with insulin resistance, body mass index (BMI), age, and sex in a combined male–female cohort. Patients and Methods: We studied 98 men and 54 women with MASLD and 74 men and 55 women without MASLD (aged 25–64 years). Participants underwent abdominal ultrasonography and fasting blood sampling, including measurements of glucose, liver enzymes, lipids, insulin, SHBG, estradiol, and testosterone. Results: SHBG levels were lower in individuals with MASLD than in controls, with a more pronounced reduction in women. MASLD status was associated with an approximately 10 nmol/L lower SHBG concentration (p < 0.0001; gender × MASLD interaction p = 0.0462). Higher estradiol levels were associated with higher SHBG concentrations (p = 0.0009), although this association differed by sex (gender × log-estradiol interaction p = 0.0147). Older age and higher total cholesterol levels were associated with higher SHBG levels, whereas higher triglyceride levels were associated with lower SHBG levels. Conclusions: SHBG showed significant associations with MASLD and with key metabolic and hormonal factors, including BMI, age, and sex. Inclusion of both men and women extends prior male-only research and provides a broader characterisation of sex-specific associations in MASLD.

1 July 2019 in Cardiologia Croatica
Verified
Journal Article
Closed access
LDLjiljana Fodor Duric
Ljiljana Fodor Duric

1 March 2017 in Cardiologia Croatica
Verified
Journal Article
Closed access
SŠSandra Karanović Štambuk
Sandra Karanović Štambuk
AJAna Jelaković
Ana Jelaković
VIVanja Ivković
Vanja Ivković
ŽDŽivka Dika
Živka Dika
VDViktor Domislović
Viktor Domislović
Bojan JelakovićBojan Jelaković
Bojan Jelaković

1 May 2024 in Journal Of Hypertension
Verified
Journal Article
Closed access
LDLjiljana Fodor Duric
Ljiljana Fodor Duric
Objective: Ischemic nephropathy underlying atherosclerotic renal artery stenosis (ARAS) gradually induces a decrease in tissue perfusion, ultimately resulting in pronounced tissue hypoxia and inflammatory kidney injury. Administration of mesenchymal stem cells (MSC) has emerged in preclinical studies as a potential choice to repair the renal microcirculation, attenuate inflammatory injury, and restore kidney function. Recent data in humans suggest that the infusion of autologous MSC can be safely performed in subjects with ARAS, leading to increased tissue oxygenation when the MSC are infused into a single renal artery. Design and method: Design and Method:In this open-label, single center, study perspective, will be enrolled adult patients with significant ARAS estimated by renal artery Doppler ultrasound velocity acceleration (average peak systolic velocity >300 cm/s) and magnetic resonance/computed tomography angiography with evident atherosclerotic stenosis (>60% lumen occlusion), and hypertension (systolic hypertension >155 mmHg and/or the use of at least two BP drugs) and/or with declining kidney function. The intervention group (n=5) will received a single infusion of MSC (2.5 × 105 cells/kg) plus standardized medical treatment; the medical treatment only group (n=5) included subjects matched for age, kidney function, and stenosis severity. We will measured cortical and medullary volumes, perfusion, and RBF using multidetector computed tomography. Tissue oxygenation will be assessed by blood oxygen level–dependent MRI and GFR by iothalamate clearance. We plan to determine the levels of the following laboratory parameters: vascular endothelial growth factor,inflammatory cytokines,Monocyte chemoattractant protein-1 and TGF at the baseline, three and six months after MSC infusion. The determination of NGALwill provide valuable insights into the safety of MSC infusion for the patient. Results: Study perspective Conclusions: Conclusion: We hypothesize that this study perspective will provide evidence regarding the safety of intra-arterial infusion of autologous MSCs in patients with ARAS. MSC infusion without revascularization of the main renal artery is associated with increased renal tissue oxygenation and cortical blood flow as well.